Challenges in oncology - Case 4. Response of metastatic gastrointestinal stromal tumor including CNS involvement to imatinib mesylate (STI-571)

被引：22

作者：

Brooks, J ^{[1
]}

Bani, JC

Fletcher, CDM

Demeteri, CD

机构：

[1] Ochsner Clin Fdn, Baton Rouge, LA USA

[2] Harvard Univ, Sch Med, Boston, MA 02115 USA

[3] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2002年 / 20卷 / 03期

关键词：

D O I：

10.1200/JCO.2002.20.3.870

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：870 / 872

页数：3

共 6 条

[1]

[Anonymous], 2001, P AM SOC CLIN ONCOL

[2]

Blanke CD, 2001, P AM SOC CLIN ONCOL, p1a

[3]

Prognosis of gastrointestinal smooth-muscle (Stromal) tumors - Dependence on anatomic site [J].

Emory, TS ;

Sobin, LH ;

Lukes, L ;

Lee, DH ;

O'Leary, TJ .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1999, 23 (01) :82-87

[4]

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. [J].

Joensuu, H ;

Roberts, PJ ;

Sarlomo-Rikala, M ;

Andersson, LC ;

Tervahartiala, P ;

Tuveson, D ;

Silberman, SL ;

Capdeville, R ;

Dimitrijevic, S ;

Druker, B ;

Demetri, GD .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1052-1056

[5]

SHIU MH, 1982, CANCER, V49, P177, DOI 10.1002/1097-0142(19820101)49:1<177::AID-CNCR2820490136>3.0.CO

[6]

2-K

← 1 →